Manufacturer record
Indo Gulf Pharmaceuticals: regulatory record
Last checked 3 November 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
2 batches manufactured by Indo Gulf Pharmaceuticals (Uttarakhand) were declared Not of Standard Quality between July 2021 and December 2024. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Most recent flagged batch: PB-105/12, Flucent Pour-on Solution (exp Nov 2025). DTL Madurai (state lab) found it not of standard quality: Sample does not conform to Label claim with respect to Identification and Content of Flumethrin. Listed in the December 2024 alert.
Records by type
2 records linked to Indo Gulf Pharmaceuticals in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches per year
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Flucent Pour-on Solution | Batch PB-105/12Mfg Dec 2023 · Exp Nov 2025 | Sample does not conform to Label claim with respect to Identification and Content of Flumethrin.Identification | DTL MaduraiState lab | Dec 2024 |
| Cefixime Dispersible Tablets I.P. (Cefexi-100) | Batch BIG -137Mfg Mar 2019 · Exp Feb 2022 | Uniformity of dispersion and Water contentUniformity of weight/content | RDTL GuwahatiCDSCO lab | Jul 2021 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.